Abstract
Purpose: To identify the possible risk factors for the development of cataract requiring surgery in children with juvenile idiopathic arthritis (JIA)-associated uveitis. Design: Retrospective cohort study. Methods: Data of 53 children with JIA-associated uveitis, of whom 27 had undergone cataract extraction (CE), were obtained. The main outcome measure, the interval between the onset of uveitis and the first CE (U-CE interval), was examined in relation to clinical and ophthalmologic characteristics and treatment strategies before CE. Results: A shorter U-CE interval was found for children with posterior synechia vs those without posterior synechia (hazard ratio [HR], 3.57; 95% confidence interval [CI], 1.33 to 10.00). No significant difference was found for children in whom the uveitis was the first manifestation of JIA vs those in whom arthritis was the first manifestation of JIA (HR, 1.59; 95% CI, 0.63 to 4.00) and children treated with periocular corticosteroid injections vs those not treated with periocular corticosteroid injections (HR, 3.23; 95% CI, 0.95 to 11.11). Children treated with methotrexate (MTX) had a longer U-CE interval than children not treated with MTX (HR, 0.29; 95% CI, 0.10 to 0.87). Conclusions: The risk factor for development of early cataract requiring surgery in children with JIA-associated uveitis is the presence of posterior synechia at the time of diagnosis of uveitis. However, early treatment with MTX is associated with a mean delay in the development of cataract requiring surgery of 3.5 years.
| Original language | English |
|---|---|
| Pages (from-to) | 574-579.e1 |
| Journal | American Journal of Ophthalmology |
| Volume | 144 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Oct 2007 |
| Externally published | Yes |
Bibliographical note
Funding Information:This study was supported by the Dr. F. P. Fischer Foundation, Utrecht, The Netherlands (Dr Sijssens), and by the ViroLab Project, which is sponsored by the European Union, Contract IST-027446 (Dr van de Vijver). The authors indicate no financial conflict of interest. Involved in design and conduct of study (K.M.S., A.R., J.H.d.B.); collection and management of the data (K.M.S., J.H.d.B.); analysis and interpretation of the data (K.M.S., A.R., D.A.M.C.v.d.V., J.S.S., J.H.d.B.); preparation of the manuscript (K.M.S., J.H.d.B.); review of the manuscript (A.R., D.A.M.C.v.d.V., J.S.S., J.H.d.B.); and approval of the manuscript (K.M.S., A.R., D.A.M.C.v.d.V., J.S.S., J.H.d.B.).